Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury

Part 1

AstraZeneca: Cancer comeback

Part 2

Cancer's future: Five trends

ARTICLE | Product Development

Oncology at AstraZeneca: The journey to the top

A Q&A with EVP of oncology R&D, Susan Galbraith: Part 1

By C. Simone Fishburn, Editor in Chief
July 20, 2024 12:16 AM UTC

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

AstraZeneca’s rise in oncology may turn out to be one of the industry’s big all-time turnaround stories. BioCentury sat down with one of its architects, Susan Galbraith, to discuss the factors behind the pharma’s growth in oncology, and where she sees cancer medicine headed from here...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Allorion Therapeutics Inc.